HRH4 and rheumatoid arthritis: Toreforant (JNJ38518168), the first oral H4R antagonist, has been explored for the treatment of RA patients with active disease despite concomitant methotrexate therapy (phase 2 trials, ClinicalTrials.gov database entry NCT01862224 and dose range finding study NCT01679951) [92,93].